Report Description of the Europe Cardiovascular Market
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for Europe Cardiovascular Market
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Europe Cardiovascular Market
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
Europe Cardiovascular Market Executive Summary
In this era, the number of critical and life-threatening diseases have shown increasing prevalence across the Europe landscape. One of these critical diseases includes cardiovascular diseases, which have shown steady increases in prevalence in Europe, especially driven by modern lifestyle changes. The cardiovascular diseases include disorders of the heart and blood vessels especially and include life-threatening conditions such as coronary heart disease, hypertension, and hyperlipidemia. Cardiovascular diseases can result in conditions such as myocardial infarction. i.e., heart attacks and strokes. According to the World Health Organization (WHO), four out of five cardiovascular disease (CVD) deaths, can be attributable to heart attacks and strokes.
Market Size and Key Findings
The Europe Cardiovascular Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 6.2% during the forecast period.
The European market for cardiovascular devices is majorly driven by an increasing number of people suffering from diabetes and obesity and growing risks related to hypertension and heart muscle weakening. Advancements in Technology have enabled portability features such as portability in performing various tests and adding to the growth of the Cardiovascular Monitoring market.
Market Dynamics
Market Growth Drivers Analysis
The key factors propelling the growth of the market is the growing incidences of cardiovascular diseases, advancements in the technology and the demand for home-based, point of care, and remote monitoring cardiac systems during the forecast period. There is also an increase in the prevalence of obesity among adults and youth that is one of the leading causes for cardiovascular diseases, which in turn boosts the market growth.
Market Restraints
Some of the factors hindering the growth of the market includes rising costs for drug development and lowering of target population. And also, despite of high prevalence, drug development pipelines for cardiovascular disorders have been stagnant for a variety of reasons.
COVID-19 impact on “Europe Cardiovascular Market”
The deferral of elective procedures due to COVID-19-related measures has negatively affected the cardiovascular medical devices market. While some cardiovascular procedures are considered urgent, others have been rescheduled and deferred since the beginning of the global pandemic. Another factor negatively affecting the cardiovascular disease market is the reduction in the diagnosis of cardiovascular diseases due to healthcare resources being reserved for COVID-19 patients.
Competitive Landscape
Key Players
The “Europe Cardiovascular Market” study report will provide valuable insights with an emphasis on the Europe market including some of the key market players such as major players including Novartis, koninklijke philips, Fresenius Medical Care, Siemens Healthineers, Smith & Nephew, Draegerwerk and Coloplast.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and revenue analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players.
Notable Recent Deals
The EAS is delighted to join the European Alliance for Cardiovascular Health (EACH) as partner organization The European Alliance for Cardiovascular Health (EACH) is a first of a kind initiative that brings together 16 leading Cardiovascular health organizations from a broad spectrum. The aim of the Alliance is to encourage the European policymakers to commit to Cardiovascular care and develop a European policy plan.
The EAS has joined the Alliance to raise awareness and encourage the policy makers to develop policies and ensure that the EU strategy matches the scale of the massive burden. The Alliance represents an opportunity and willingness to better coordinate investments, research, innovations and alignment between countries.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
Despite the far-reaching impact of HF, governments have been slow to recognize its significance. Of the 11 European countries included in this work, most lack a dedicated strategy on HF, and where plans are available, they are often out of date or underfunded. Existing cardiovascular or non-communicable disease policy initiatives commonly neglect HF, despite it falling into their scope.
